Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Inks Southeast Asian Marketing Deal for Breast Cancer Tests

NEW YORK (GenomeWeb) – Agendia said today that it has signed a marketing agreement with Angsana Molecular & Diagnostics Laboratory for Agendia's MammaPrint and BluePrint breast cancer tests in Southeast Asia.

MammaPrint analyzes 70 genes associated with breast cancer recurrence to provide a binary low or high risk of cancer recurrence to help physicians decide which individuals can forgo chemotherapy. BluePrint includes 80 genes and classifies a patient's breast cancer into one of four functional molecular subtypes.

Under the terms of the deal, diagnostic developer Angsana will market the tests to physicians in Singapore, Malaysia, Vietnam, Brunei, and Myanmar.  

Additional terms were not disclosed.

"Southeast Asia represents a significant growth opportunity for Agendia and a commercial priority for the company," Agendia Chief Commercial Officer Chris Barbazette said in a statement. "With their extensive experience in molecular diagnostics and regional insight, Angsana is an ideal partner as we continue to build our presence in this rapidly evolving market."

In addition to its own diagnostics, Singapore-based Angsana offers tests from Admera Health and Counsyl in Asia.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.